146 related articles for article (PubMed ID: 37042242)
1. Enhancing the Detection and Care of Heterozygous Familial Hypercholesterolemia in Primary Care: Cost-Effectiveness and Return on Investment.
Marquina C; Morton J; Brett T; Lloyd M; Radford J; Heal C; Hespe C; Gill G; Sullivan D; Zomer E; Li I; Pang J; Watts GF; Ademi Z
Circ Genom Precis Med; 2023 Jun; 16(3):267-274. PubMed ID: 37042242
[TBL] [Abstract][Full Text] [Related]
2. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands.
Ademi Z; Norman R; Pang J; Sijbrands E; Watts GF; Hutten BA; Wiegman A
JAMA Pediatr; 2023 Jun; 177(6):625-632. PubMed ID: 37126315
[TBL] [Abstract][Full Text] [Related]
4. The economic impact of familial hypercholesterolemia on productivity.
Ademi Z; Marquina C; Zomer E; Bailey C; Owen A; Pang J; Norman R; Watts GF; Liew D
J Clin Lipidol; 2020; 14(6):799-806.e3. PubMed ID: 32928710
[TBL] [Abstract][Full Text] [Related]
5. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.
Marquina C; Lacaze P; Tiller J; Riaz M; Sturm AC; Nelson MR; Ference BA; Pang J; Watts GF; Nicholls SJ; Zoungas S; Liew D; McNeil J; Ademi Z
Eur Heart J; 2022 Sep; 43(34):3243-3254. PubMed ID: 34788414
[TBL] [Abstract][Full Text] [Related]
6. Heterozygous familial hypercholesterolemia: prevalence and control rates.
Polychronopoulos G; Tzavelas M; Tziomalos K
Expert Rev Endocrinol Metab; 2021 Jul; 16(4):175-179. PubMed ID: 33993819
[No Abstract] [Full Text] [Related]
7. The detection of heterozygous familial hypercholesterolemia in Ireland.
O'Kane MJ; Menown IB; Graham I; Maher V; Tomkin G; Nicholls P; Graham C
Adv Ther; 2012 May; 29(5):456-63. PubMed ID: 22610724
[TBL] [Abstract][Full Text] [Related]
8. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M
Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
[TBL] [Abstract][Full Text] [Related]
9. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
[TBL] [Abstract][Full Text] [Related]
10. Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia.
Cao YX; Zhou BY; Sun D; Li S; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Liu G; Dong Q; Li JJ
Per Med; 2019 Nov; 16(6):467-478. PubMed ID: 31691639
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
12. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
[TBL] [Abstract][Full Text] [Related]
13. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease.
Yuan G; Wang J; Hegele RA
CMAJ; 2006 Apr; 174(8):1124-9. PubMed ID: 16606962
[TBL] [Abstract][Full Text] [Related]
14. Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) - Results of a US national survey.
Block RC; Bang M; Peterson A; Wong ND; Karalis DG
J Clin Lipidol; 2021; 15(5):682-689. PubMed ID: 34593357
[TBL] [Abstract][Full Text] [Related]
15. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
[TBL] [Abstract][Full Text] [Related]
16. Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
Marco-Benedí V; Laclaustra M; Bea AM; Suarez-Tembra M; Plana N; Pinto X; Brea A; Sanchez-Hernandez RM; Civeira F
Atherosclerosis; 2021 Mar; 320():47-52. PubMed ID: 33529866
[TBL] [Abstract][Full Text] [Related]
17. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
[TBL] [Abstract][Full Text] [Related]
18. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
20. Genetic Identification of Homozygous Familial Hypercholesterolemia by Long-Read Sequencing Among Patients With Clinically Diagnosed Heterozygous Familial Hypercholesterolemia.
Chaudhry A; Trinder M; Vesely K; Cermakova L; Jackson L; Wang J; Hegele RA; Brunham LR
Circ Genom Precis Med; 2023 Apr; 16(2):e003887. PubMed ID: 36960729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
